BioCryst Pharmaceuticals Stock Earnings Report
Current P/E ratio: -10.27 | Price (May 26, 2023, EOD): $8.01 (Find current average P/E ratios for all sectors below)
BCRX Upcoming Earnings (Q2 2023)
| Earnings Date: | Aug 02, 2023 |
| Consensus EPS: | Premium |
BCRX Analysts Price Targets
Currently no data available.About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitor that is in Phase I clinical trial to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Last 3 Quarters for BCRX Premium
Below you can see how BCRX performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
What Is an Earnings Report?
An earnings report is usually issued quarterly (Q1, Q2, Q3 & Q4) by public companies to report their performance. Earnings reports typically include net income, earnings per share, earnings from continuing operations, and net sales. Looking at the earnings report investors can start gauge the financial health of the company and make even better decisions whether to buy, sell, or stay in the company. Fundamental analysts and value investors will typically hunt for stocks that continue to show good financial ratios and use a decline as an exit point. One of the most anticipated numbers for analysis is earnings per share because it indicates how much the company earned for its shareholders. The report will also indicate a possible dividend.
Earnings Report Content
Earnings reports generally provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. These figures are typically measured against previous quarters/years. Furthermore, the earnings report usually includes a summary and analysis from the CEO or company spokesman, alongside a more general view of the financials and future forecast.
What To Know About Earnings Reports
Announcement of earnings for a stock, particularly for well followed large-capitalization stocks, can move the market. Stock prices can fluctuate wildly on days when the quarterly earnings report is released. Despite good reports, stocks may very well fall if the investors were expecting more or they believe the next quarter will not be as good. Investors always try to be ahead of the market and future earnings/losses are often discounted into the current price of the stock. It is natural for stocks to start to move in either direction a few days before the release of an earnings report.
Average Sector P/E ratio
Is your stock priced above or below the average P/E ratio?
A higher P/E ratio shows that investors are willing to pay a higher share price today because of growth expectations in the future. For example, a company with a current P/E of 25, trades at 25 times today's earnings.
| Name | Number of firms | Average PE |
|---|---|---|
| Advertising | 47 | 20 |
| Aerospace/Defense | 77 | 35 |
| Air Transport | 18 | 15 |
| Apparel | 51 | 26 |
| Auto & Truck | 13 | 15 |
| Auto Parts | 46 | 16 |
| Bank (Money Center) | 7 | 11 |
| Banks (Regional) | 611 | 17 |
| Beverage (Alcoholic) | 21 | 38 |
| Beverage (Soft) | 34 | 35 |
| Broadcasting | 27 | 14 |
| Brokerage & Investment Banking | 39 | 14 |
| Building Materials | 42 | 23 |
| Business & Consumer Services | 165 | 32 |
| Cable TV | 14 | 156 |
| Chemical (Basic) | 43 | 14 |
| Chemical (Diversified) | 6 | 10 |
| Chemical (Specialty) | 94 | 25 |
| Coal & Related Energy | 22 | 7 |
| Computer Services | 106 | 27 |
| Computers/Peripherals | 48 | 24 |
| Construction Supplies | 44 | 22 |
| Diversified | 23 | 45 |
| Drugs (Biotechnology) | 503 | 77 |
| Drugs (Pharmaceutical) | 267 | 22 |
| Education | 35 | 21 |
| Electrical Equipment | 113 | 28 |
| Electronics (Consumer & Office) | 20 | 18 |
| Electronics (General) | 153 | 49 |
| Engineering/Construction | 54 | 24 |
| Entertainment | 107 | 150 |
| Environmental & Waste Services | 82 | 70 |
| Farming/Agriculture | 31 | 63 |
| Financial Svcs. (Non-bank & Insurance) | 232 | 36 |
| Food Processing | 88 | 55 |
| Food Wholesalers | 17 | 43 |
| Furn/Home Furnishings | 35 | 17 |
| Green & Renewable Energy | 22 | 88 |
| Healthcare Products | 242 | 160 |
| Healthcare Support Services | 128 | 131 |
| Heathcare Information and Technology | 129 | 132 |
| Homebuilding | 32 | 64 |
| Hospitals/Healthcare Facilities | 36 | 145 |
| Hotel/Gaming | 65 | 171 |
| Household Products | 127 | 26 |
| Information Services | 69 | 283 |
| Insurance (General) | 19 | 693 |
| Insurance (Life) | 24 | 15 |
| Insurance (Prop/Cas.) | 51 | 71 |
| Investments & Asset Management | 192 | 120 |
| Machinery | 120 | 27 |
| Metals & Mining | 92 | 37 |
| Office Equipment & Services | 22 | 16 |
| Oil/Gas (Integrated) | 4 | 13 |
| Oil/Gas (Production and Exploration) | 269 | 19 |
| Oil/Gas Distribution | 24 | 606 |
| Oilfield Svcs/Equip. | 136 | 28 |
| Packaging & Container | 24 | 43 |
| Paper/Forest Products | 15 | 20 |
| Power | 52 | 28 |
| Precious Metals | 83 | 98 |
| Publishing & Newspapers | 31 | 28 |
| R.E.I.T. | 234 | 91 |
| Real Estate (Development) | 20 | 146 |
| Real Estate (General/Diversified) | 12 | 31 |
| Real Estate (Operations & Services) | 57 | 23 |
| Recreation | 63 | 50 |
| Reinsurance | 2 | 153 |
| Restaurant/Dining | 77 | 66 |
| Retail (Automotive) | 26 | 20 |
| Retail (Building Supply) | 17 | 202 |
| Retail (Distributors) | 80 | 28 |
| Retail (General) | 18 | 22 |
| Retail (Grocery and Food) | 13 | 38 |
| Retail (Online) | 70 | 319 |
| Retail (Special Lines) | 89 | 25 |
| Rubber& Tires | 4 | 15 |
| Semiconductor | 72 | 109 |
| Semiconductor Equip | 39 | 26 |
| Shipbuilding & Marine | 10 | 30 |
| Shoe | 11 | 27 |
| Software (Entertainment) | 86 | 60 |
| Software (Internet) | 30 | 90 |
| Software (System & Application) | 363 | 144 |
| Steel | 32 | 11 |
| Telecom (Wireless) | 18 | 27 |
| Telecom. Equipment | 91 | 66 |
| Telecom. Services | 67 | 115 |
| Tobacco | 17 | 33 |
| Transportation | 18 | 24 |
| Transportation (Railroads) | 8 | 20 |
| Trucking | 33 | 18 |
| Utility (General) | 16 | 26 |
| Utility (Water) | 17 | 46 |
| Total Market | 7053 | 61 |
| Total Market (without financials) | 5878 | 62 |
Updated: Jan 2020
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
